Vertex Pharmaceuticals Logo

Email this page: News Release

Vertex Receives CHMP Positive Opinion for ORKAMBI® (lumacaftor/ivacaftor) for the Treatment of Children with Cystic Fibrosis Ages 6-11 with Two Copies of the F508del Mutation in the European Union

For security reasons, registration is required before you can use this feature.
* Indicates required field